[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556413":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":18,"responsibleParty":29,"collaborators":18,"id":33,"slug":18,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":18,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":18,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":54,"whyStopped":18,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":18},{"fullName":5,"class":6},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"brachytherapy","EXPERIMENTAL","Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.",[13],"Radiation: brachytherapy",[15],{"type":16,"name":9,"description":11,"armGroupLabels":17,"otherNames":18},"RADIATION",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Xiaojing Yang, Dr","CONTACT","86-21-2405-8972","yangxj717@163.com",{"name":26,"role":22,"phone":27,"phoneExt":18,"email":28},"Jie Fu, Dr","86 21 24058973","fujie74@sjtu.edu.cn",{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Xiaojing Yang","Principal Investigator","100556413",false,"NCT06524778","Single High-dose Brachytherapy for Giant Osteosarcoma Masses","The Therapeutic Effect of Single High-dose Brachytherapy for Locally Inoperable and Metastatic Giant Osteosarcoma Masses","Inclusion Criteria:\n\n1. Pathological diagnosis of osteosarcoma;\n2. Age range 12-70 years old;\n3. The primary or metastatic lesion cannot be surgically removed based on clinical evaluation, and treatment with internal medicine multi line chemotherapy, targeted therapy, immunotherapy, etc. is ineffective;\n4. ECOG physical fitness status is 0-1 points;\n5. According to RECIST version 1.1 standard, there must be at least one evaluable target lesion with a mass length diameter greater than 5cm;\n6. Sign a written informed consent form before conducting any experimental activities;\n7. Researchers determine that they are able to comply with the research protocol;\n8. Patients who are willing and able to comply with visit arrangements, treatment plans, laboratory tests, and other research procedures.\n\nExclusion Criteria:\n\n1. Local mass previously received radiation therapy;\n2. Major surgery ≤ 4 weeks before enrollment;\n3. Previous or concurrent malignant tumors (excluding malignant tumors that have been cured and have a cancer free survival of more than 5 years, such as basal cell carcinoma of the skin and papillary thyroid carcinoma);\n4. Pregnant or lactating women;\n5. Active pulmonary tuberculosis.","ALL","12 Years","70 Years",{"count":43,"type":44},16,"ESTIMATED","INTERVENTIONAL",[47],"PHASE2","This study is a prospective, single-arm, phase II, single-center study. Patients with locally unresectable giant osteosarcoma masses who meet the criteria are enrolled in the experimental group, and all patients receive a single dose of 10Gy of implantable brachytherapy. Record treatment-related acute events during and after treatment. Follow up on survival and local control after treatment ends, marking the end of the trial treatment.",[50],"Osteosarcoma",[9,52,53],"high-dose","osteosarcoma","NOT_YET_RECRUITING","2024-08-05",{"date":57,"type":58},"2024-08-07","ACTUAL",{"date":60,"type":44},"2024-08-30",{"date":62,"type":44},"2027-06-30",{"name":5,"class":6}]